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Summary Folinic acid (FA) and cisplatin (CIDDP) both potentiate the cytotoxicity of 5-fluorouracil (5-FU).
The activity of various drug combinations including 5-FU, CDDP and FA was tested on two human cell lines
derived from squamous cell carcinomas of the head and neck. Cytotoxicity was assessed by the semi-
automated colorimetric MTT test. The drugs were tested in clinically achievable conditions (concentrations
and duration of exposure). The dose response curves for 5-FU (0-100 ng ml-') associated with FA
(I-7- 10' M) reflected a progressive increase in 5-FU cytotoxicity with increasing FA concentrations. When
CDDP (0-5 lgml ') was associated with 5-FU, CDDP-mediated enhancement of 5-FU cytotoxicity was
apparent only when CDDP was given before 5-FU. The triple association CDDP, 5-FU and FA was also
tested. In this case, for an identical final cytotoxicity, the presence of FA (10-6 M) permitted reduction of the
5-FU concentration between 24.2 and 42% and reduction of the CDDP concentration between 13.8 and
72.7%. These observations may be beneficial for the design of more rational therapeutic trials associating
CDDP, 5-FU and FA.
5-fluorouracil (5-FU) is increasingly used in the treatment of
several types of malignancies, although not because of the
efficacy of the drug itself. For example, even though 5-FU is
widely used for the management of colorectal adenocar-
cinoma, it still has a disappointingly low efficacy when
administered alone in this pathology (Moertel, 1978; Cohen
et al., 1989). The renewed interest is linked to the results
obtained with various drug combinations, and in particular
5-FU plus cisplatin (CDDP) for treatment of head and neck
cancer (Kish et al., 1982; Amrein & Weitzman, 1985; Thyss
et al., 1986), and 5-FU plus folinic acid (FA), which
significantly improves the response rate in colorectal car-
cinoma (Machover et al., 1986; Rustum, 1989; O'Connell,
1989; Arbuck, 1989). The improved results obtained when
5-FU is administered in combination can be explained
biochemically: reduced folates enhance the inhibition of
thimidilate synthetase (TS) by 5-fluoro-2'-deoxyuridine-5'-
monophosphate (FdUMP), an active form of 5-FU (Hough-
ton et al., 1982; Kerr, 1989). Although less work has been
conducted on 5-FU potentiation by CDDP, a cisplatin-
induced increase in intracellular levels of reduced folates may
also be the central mechanism in CDDP-5-FU synergism
(Scanlon et al., 1986). Tests of the triple association 5-FU-
CDDP-FA were a logical consequence; not surprisingly, the
first noncontrolled clinical trials have been reported recently.
Objective responses have been observed for heavily
pretreated patients with breast (Hart et al., 1989; Allegra et
al., 1989), gastrointestinal (Leong et al., 1989; Fernandes et
al., 1989), and head and neck carcinomas (Vokes et al.,
1989). However, severe toxicity has also occurred, and has
reportedly caused a number of deaths (Leong et al., 1989).
These clinical trials differed considerably as concerns the
drug sequences and dosages of 5-FU, CDDP and FA. Experi-
mental data are required to develop rational guidelines for
optimizing synchronisation of these three products and for
analysis of the relative roles of CDDP and FA when com-
bined with 5-FU. In an attempt to obtain such information,
the present experimental study was developed using human
cell cultures from head and neck carcinoma.
Material and method
Chemicals
5-FU was obtained from ROCHE Laboratories (Neuilly,
France), in an injectable form dissolved in H20 (final concen-
tration 0.385 M). CDDP was obtained from R. Bellon Lab-
oratories (Paris, France), in an injectable form dissolved in
0.9% NaCl (final concentration 1.66 10-3 M). FA (d,l) was
obtained from Sigma (La Verpilliere, France), as a powder
that was dissolved just before use in H20 at a final concen-
tration of 10-2 M. These stock solutions were stored at
-200C.
The MTT test (Carmichael et al., 1987) was performed
with 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bro-
mide (MTT) and DMSO, both from SIGMA.
DMEM medium, glutamine and foetal bovine serum (FBS)
were purchased from GIBCO (Paisley, GB). Penicillin and
streptomycin were from MERIEUX (Lyons, France).
Cell lines CAL 27 and CAL 33 were established in our
institute (Gioanni et al., 1988) from squamous cell car-
cinomas of the head and neck; they were obtained from
tumour fragments excised prior to any treatment. The doub-
ling times were measured during exponential growth: 35 h for
CAL 27, 43 h for CAL 33.
Experimental conditions
Cells were routinely cultured in a humidified incubator
(Sanyo) at 37°C with an atmosphere containing 8% CO2 in
air. Initial cell densities were 2,500 cells per well (96-well
plates). Four different types of experiments were performed
(Table I): analysis of the specific effects of CDDP; analysis of
the association 5-FU-FA (products given simultaneously);
analysis of the association 5-FU-CDDP (effect of the order);
analysis of the combination CDDP-5-FU-FA; in this last
experiment, the preliminary results of the CDDP-5-FU as-
sociation were known, so CDDP was given prior to the
simultaneous association of 5-FU and FA. Experiments were
repeated after an interval of 12 months.
Evaluation ofcytotoxicity
The cytotoxic effects of the different drug combinations were
assessed by the MTT semi-automated test (Carmichael et al.,
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Table I Experimental conditions
Conditions Drug(s) used Concentrations Exposure Cell line(s)
CDDP alone CDDP 0-100 gml-' 2h CAL27, CAL 33
Association 5-FU 0-100 ng ml-' together, CAL27, CAL 33
5FU-FA FA 0_10-710-6_10-5 M 5 days
Association 5-FU 0-100 ngml' 5 days CAL27
CDDP-5FU CDDP 0,1,2.5,5 sg ml' 2 h:
-6 h or 24h
before 5-FU
-together with 5-FU
(1/5 of the total
dose each day)
-6 h or 24 h
after 5-FU
Association 5-FU 0,2,5,10,25 ng ml-' together with CAL 27
CDDP-5FU-FA FA 3 days,
CDDP 0,1,2.5,5pg ml-' 2 h, 6 h before
5-FU-FA
FA 0-10-7 M10-6 M together with 5-FU
3 days
1987) after 6-8 days ofexposure in 96-well incubating plates.
The MTT incubation time was 4 h. Results were expressed as
the relative percentage of absorbance compared to controls
without drugs. Absorbance was set at 540 nm and measured
on a Titerteck Twinreader. Each dose point was performed
in sextuplicate. IC50 was defined as the drug concentration
causing a 50% reduction in growth compared to controls.
Results
Figure 1 shows the dose response curves of cell lines CAL 27
and CAL 33 to CDDP alone (concentration range
0-I00jg ml-'). Both cell lines are sensitive to CDDP, but to
different degrees; the IC50 for CAL 27 and CAL 33 was

















Figure 1 Dose response curves with CDDP for cell lines CAL 27
a, and CAL 33 b. For CAL 27 and CAL 33, the data were best fit
by sigmoid curves (log scale); the respective r2 values were 0.990
and 0.940 (P<0.001). Vertical bars= s.d.
The dose response curves for 5-FU combined with FA are
shown on Figure 2 for various FA concentrations (10-7 to
10-5 M). 5-FU activity increased progressively for both cell
lines as the FA concentration rose. When the FA concentra-
tion changed from 0 to 10-5 M, the ICm (ngml-') for
CAL 27 and CAL 33 changed from 27.1 to 9.7 and from 44.4
to 27.1 respectively (Table II).
Figure 3 shows the dose response curves for cell line
CAL 27 when 5-FU was combined with CDDP before, dur-
ing and after exposure to 5-FU. CDDP-mediated enhance-
ment of 5-FU cytotoxicity was apparent only when CDDP
was given before or at the same time as 5-FU. It can be seen
that the data compare well from the two separate experi-
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Figure 2 Dose response curves with 5-FU in the presence of FA
for cell lines CAL 27 a, and CAL 33 b. For CAL 27 and CAL 33,
the data were best fit by sigmoid curves (log scale). The r2 values
for the various FA concentrations ranged between 0.970 and
0.995 for CAL 27 and between 0.937 and 0.986 for CAL 33
(P<0.00). Vertical bars= s.d.374 M.C. ETIENNE et al.
Table II IC50 values of 5-FU for head and neck carcinoma cell lines
exposed to 5-FU and FA
5-FU (ngml')
Cell lines no FA FA 10-7M FA 1o6M FAJOsM
CAL 27 27.1 24.3 13.6 9.7
CAL 33 44.4 37 36.8 27.1
IC50 values calculated from data on Figure 2 (sigmoid curve
equations).
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Figure 3 Combined effects ofCDDP and 5-FU on the inhibition
of CAL 27 cell growth. a and b are separated experiments done
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Figure 4 Correlations between observed and theoretical (pre-
dicted) cytotoxic effects of CDDP and 5-FU on CAL 27. Data
points were obtained from experimental data shown on Figure
3a, (5-FU range 0-lOOngml-'; CDDP range 0-51Lgml-').
Predicted effect: product of the specific effect of 5-FU multiplied
by the specific effect ofCDDP for a given combination. a, CDDP
6 h before 5-FU; b, CDDP and 5-FU together; c, CDDP 6 h
after 5-FU. For details see Table I; dotted lines = regression lines
for the data shown; solid lines = 95% confidence interval; dashed
lines = theoretical line for equivalence between observed and
theoretical effects. Statistics: for a, the Wilcoxon rank test gave a
two-tailed probability P = 0.0284; Spearman rank-correlation
r = 0.959, P = 0.0024. For b, the Wilcoxon rank test gave a
two-tailed probability P = 0.1973; Spearman rank-correlation
r = 0.964, P = 0.0023. For c, the Wilcoxon rank test gave a
two-tailed probability P = 0.0684; Spearman rank-correlation
r = 0.950, P= 0.0027.
= 1 fig ml1') to 24.2% (CDDP concentration = 2.5 yg ml1 );
inversely, the CDDP concentration could be reduced from
13.8% (5-FU concentration = 10 ng ml') to 72.7% (5-FU
concentration = 17.5 ng mlh') (Table III).
tion, Figure 4 compares the cytotoxic effects actually
produced by the drug combination with the effects predicted
from results obtained with each drug used alone. These
graphs and statistical analysis reveal that administration of
CDDP before 5-FU leads to more than additive effects; by
contrast, when CDDP was administered at the same time as
5-FU, mere additivity of the effects was noted; finally, when
CDDP was used after 5-FU, less than addivity of effects
occurred (observed effects lower than predicted effects, with a
trend towards statistical significance). The data shown for the
sequence CDDP followed by 5-FU concern a lag time of 6 h;
similar results were obtained for a lag time of 24 h.
Figure 5 shows the cytotoxic effects of the triple associa-
tion CDDP, 5-FU and FA on cell line CAL 27. For each
experiment (Figure 5a and 5b) the dose response curves
reflect a progressive increase in cytotoxicity when the FA
concentration changed from 0 to 10-6 M. Figure 6 shows the
iso-effect cuves at IC50. For a given IC50, use of FA 10-6 M,
compared to conditions without FA, allowed reduction of
the 5-FU concentration of from 42% (CDDP concentration-
Discussion
Most experimental results concerning use of 5-FU/FA associ-
ations have been obtained with colorectal carcinoma cell lines
(Park et al., 1988), leukaemic cells (Kane et al., 1987; Bert-
rand & Jolivet, 1989; Keyomarsi & Moran 1986, 1988), and
nasopharyngeal epidermoid cells (Kane et al., 1987). This in
vitro study confirms and strengthens the findings of these
earlier reports by demonstrating that 5-FU activity on
human head and neck squamous cell carcinoma cell lines can
be potentiated by both CDDP and FA. Careful attention was
paid to use of clinically relevant drug concentrations. 5-FU
exposure at a dose of 10-100 ngml-' for 5 days compares
well with the concentrations reported in patients treated by
continuous, 5-day infusions (Fraile et al., 1980). Total con-
centration x time exposure (AUC) of CDDP ranged from 2
to 10jg hrml-'; pharmacokinetic studies for patients treated
by 2 h infusions indicate AUC values between 1.75 and
8.33-gig hrml' (Reece et al., 1989). Repeated oral admini-
stration of leucovorin during 5 days leads to plasma concen-
t-uur o nr arier o ru
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Figure 5 Combined effects of CDDP, 5-FU and FA on the inhibition of CAL 27 cell growth. a and b are separated experiments
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Figure 6 Iso-effect curves at IC" for the combination CDDP,
5-FU and FA on CAL 27. Data points were obtained by inter-
polation of cell growth inhibition at 50% on the respective curves
shown on Figure 5a. The points were best fit by the equation
y = ax + b. For FA = 0, FA = 17-7M and FA = l0-6M; r2 was
respectively 0.9652 (P<0.001), 0.9720 (P<0.001), 0.9503
(P<0.01). The three regression lines were significantly different
from one other: nonparametric ANOVA (Friedman test):
X2= 6.00 (2df), P<0.05.
trations of around 3 gLM (Schilsky et al., 1989); in the present
study, cells were exposed for 3-5 days to FA concentrations
of 10- to 10- M. Keeping in mind the differences between
in vitro and in vivo situations, our experimental conditions
(drug concentrations and the durations of cell exposure)
appear pharmacologically achievable, and permit more satis-
factory extrapolation of the present findings to the actual
clinical situations.
The experiments were performed in a non-folate depleted
medium. Theoretically, use of a folate-depleted medium
would have allowed more precise evaluation of the specific
role of FA on the activity of 5-FU. However, as stressed by
others (Park et al., 1988), such tests could have resulted in
overestimation of the effects of FA in comparison to physio-
logical situations in which patients are not folate-deficient.
On the other hand, the FA preparation contains an equi-
molar ratio of the natural (-1) and unnatural (-d) stereo-
isomers, and it is generally accepted that only the natural
isomer is active. Parenteral administration of FA results in a
very different blood behaviour of d/l FA, with a slower
elimination phase of the unnatural isomer (Machover et al.,
1986). This raises the possibility that the -d FA might
interfere with the isomer's enhancement of 5-FU cytotoxicity.
This eventuality was not tested in the present study, because
earlier reports (Bertrand & Jolivet, 1989) demonstrated that
the d-isomer did not impair 5-FU cytotoxicity enhancement
by the 1-isomer in similar tissue culture experiments.
Ever since the pioneer work of Dionet and Verrelle (1984),
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Table III ICo values of5-FU and CDDP for head and neckcarcinoma cell line CAL 27
exposed to CDDP, 5-FU and FA
CDDP 5-FU (ng ml-') Reduction* in 5-FU
concentration no FA FA 10-7M FA 10-6 M concentration %
11igml-, 25 18.5 14.5 42
1.65pg ml-' 20.7** 17.7** 13.8** 33.3
2.5 ig ml- 16.5 16 12.5 24.2
5-FU CDDP (ygml-') Reduction* in CDDP
concentration no FA FA 10-7 M FA 10-6 M concentration %
10 ngml-' 2.9 3.2 2.5 13.8
15 ngml-' 2.5 2.5 1 60
17.5 ngml-' 2.2 1.65 0.6** 72.7
*Reduction in drug exposure (5-FU or CDDP) allowed by FA, calculated as follows:
ICo (FA 10-6 M) x 100
IC5o (no FA)
**Values calculated using the regression lines on Figure 1.
treatment of advanced head and neck cancers (Kish et al.,
1982; Amrein & Weitzman, 1985; Thyss et al., 1986). How-
ever, up until now, there has been a lack of experimental
investigations on the sequence-dependence of CDDP and
5-FU in this association. The present data suggest that
CDDP administration before 5-FU potentiates the activity of
the antimetabolite; simultaneous exposure to the two drugs
results in simple additivity of their effects whereas the se-
quence 5-FU followed by CDDP gives lesser effects than
could be expected. Considering that CDDP may promote
increased intracellular retention of reduced folates (Scanlon
et al., 1986), pre-exposure to CDDP leading to increased
5-FU activity appears pharmacologically coherent (Houghton
et al., 1982). These findings confirm the report by Scanlon et
al., 1986) concerning human ovarian carcinoma line A 2780
in culture; for these authors, CDDP followed by 5-FU was
more cytotoxic than the opposite sequence or either drug
used alone. However, these observations are in apparent
contradiction with the recent work by Pratesi et al. (1988),
who analysed the sequence-dependence of the antitumour
effect of a 5-FU-CDDP combination on chemically-induced
colon tumours in a murine model. For these authors, 5-FU
followed 24 h later by CDDP was the most active sequence.
The relevance of their experimental model can be questioned,
though, because of 5-FU alone had only marginal activity
compared to CDDP, which was more effective.
Consistent clinical data having demonstrated 5-FU poten-
tiation by CDDP (Kish et al., 1982; Amrein & Weitzman,
1985; Thyss et al., 1986; Scanlon et al., 1986) and FA
(Machover et al., 1986; Rustum, 1989; O'Connell, 1989;
Arbuck, 1989; Houghton et al., 1982), it was tempting to test
a combination of all three drugs. Not surprisingly, limited
noncontrolled trials of this drug combination have appeared
recently (Hart et al., 1989; Allegra et al., 1989; Fernandes et
al., 1989; Vokes et al., 1989). To date, little attention has'
been paid to the sequencing of the three drugs, a fundamen-
tal parameter influencing the effectiveness of this multiagent
association. Our experimental data obtained with cell cul-
tures of head and neck squamous cell carcinoma may shed
some light on this important question. For a constant final
cytotoxicity, administration of CDDP followed 6 h later by
5-FU plus FA (10-6 M) permitted reduction of the 5-FU dose
between 24.2% and 42% or reduction of the CDDP dose
between 13.8% and 72.7%. FA thus offers a means of
significantly reducing exposure to potentially toxic drugs such
as 5-FU and CDDP without loss of efficacy. Although
definite benefits in terms of an improved therapeutic index
remain to be proven clinically, these observations, obtained
with clinically achievable drug concentrations, may allow the
design of more rational therapeutic trials combining CDDP,
5-FU, and FA.
The authors wish to thank Nancy Rameau for assistance in transla-
tion.
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